Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (4937)	3/10/1999 1:57:00 PM
From: LT	Read Replies (1) \| Respond to of 5736

RE: SPRX Hmmmmmmmmm and CCSI just couldn't think of one little old reason their stock was tanking....how about huge competition coming to a rather a narrow market. Someone, insiders I would guess, knew this was coming and started selling off last week, seems so anyhow. LT

To: Cacaito who wrote (4937)	3/10/1999 2:10:00 PM
From: JanyBlueEyes	Read Replies (1) \| Respond to of 5736

Cacaito <<CCSI has no partner.>> At the moment this is a true statement which also means CCSI gets 100% of revenues generated from sales of their device (which I hear are going extremely well). Spectrx's device has been available in Europe for some time now and if you look at their quarterly reports.....sales aren't that good. There is a reason for this. <<No signifcant difference between devices.>> This is an inaccurate statement. One of the main differences is the FACT that Spectrx's device CAN NOT be used once an infant begins phototherapy treatment (a therapy that all hospitals utilize in the treatment of Jaundice). The Spectrx device is not FDA cleared for it either. <<USA market as per Sprx: $30 millions.>> This statement is wrong. Per the news release today Spectrx claims "20 million annual bilirubin blood tests worldwide". <<CCSI is in a tough position.>> This statement is wrong imo.